BioIVT completed the acquisition of PrecisionMed.

BioIVT, a global provider of research models and value-added research services for drug discovery and development, completed the acquisition of PrecisionMed, a supplier of human biological material for research. Financial terms were not disclosed. "We are thrilled to announce BioIVT's acquisition of PrecisionMed. Our vision is to lead the biospecimen industry through expertise and innovation and our acquisition of PrecisionMed pushes us even closer to this goal. We are excited about the possibilities that lie ahead as we expand our supply network and inventory and strengthen our capacity to meet the increasing customer demand for CSF and liquid biopsy products. Together, we will drive even greater value for our customers and further our mission of enabling smarter science," Richard Haigh, BioIVT CEO.